084650 — Labgenomics Co Cashflow Statement

0.000.00%

Last trade - 00:00

HealthcareHighly SpeculativeSmall CapFalling Star

Annual cashflow statement for Labgenomics Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.

	2020 December 31st	2021 December 31st	2022 December 31st	2023 December 31st	2024 December 31st
Period Length:	12 M	12 M	12 M	12 M	12 M
Source:	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts	Annual Audited Accounts
Standards:	IFRS	IFRS	IFRS	IFRS	IFRS
Status:	Final	Final	Final	Final	Final
Net Income/Starting Line	42,764	83,855	47,926	-5,246	-23,904
Depreciation
Amortisation
Non-Cash Items	17,449	21,329	20,113	1,520	7,503
Unusual Items
Equity in Net Earnings/Losses
Other Non-Cash Items
Changes in Working Capital	-17,268	-42,443	-2,136	252	-6,193
Change in Accounts Receivable
Change in Inventories
Change in Prepaid Expenses
Change in Other Assets
Change in Accounts Payable
Change in Accrued Expenses
Change in Taxes Payable
Change in Other Liabilities
Other Operating Cash Flow
Cash from Operating Activities	46,372	66,081	69,869	2,422	-12,995
Capital Expenditures	-1,515	-13,815	-38,330	-5,196	-4,547
Purchase of Fixed Assets
Purchase / Acquisition of Intangibles
Other Investing Cash Flow Items	-7,071	-12,246	-14,988	-111,408	786
Sale of Fixed Assets
Sale/Maturity of Investment
Purchase of Investments
Other Investing Cash Flow
Cash from Investing Activities	-8,586	-26,061	-53,317	-116,604	-3,762
Financing Cash Flow Items	100	0	—	-72.7	47.1
Other Financing Cash Flow
Total Cash Dividends Paid
Net Issuance / Retirement of Stock
Net Issuance / Retirement of Debt
Cash from Financing Activities	-960	-7,194	11,445	57,646	-2,229
Foreign Exchange Effects
Beginning Cash Balance
Ending Cash Balance
Net Change in Cash	35,837	32,694	27,982	-56,186	-17,814